Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

 
• By Alaric DeArment

ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.

Pills for Pre-Exposure Prophylaxis (PrEP) to prevent HIV with PrEP text engraved

More from Clinical Trials

More from R&D